Internal Medicine Alert – January 30, 2006
January 30, 2006
View Issues
-
A Novel Treatment for Diabetic Foot Ulcers
Tretinoin solution helps heal diabetic foot ulcers. -
Osteoporosis Medications: Are your Patients Really Taking Them?
A 6-year retrospective study shows that 45% of Medicare patients with state-funded drug benefits who initiate a medication for osteoporosis do not continue to take it as prescribed one year later and 52% are no longer compliant 5-years later. -
Metabolic Syndrome: A Warning of Cardiovascular Disease and Type 2 Diabetes Mellitus?
Metabolic syndrome is common and is associated with an increased risk for CVD and T2DM in both sexes. -
Gastric Acid-Suppressive Agents and Risk of Community-Acquired C. difficile
Acid suppression, particularly with proton pump inhibitors (PPIs) is correlated with an increased risk of community-acquired Clostridium difficile colitis. -
Pharmacology Update: Levalbuterol Tartrate Inhalation Aerosol (Xopenex HFA)
The FDA has approved a cfc-free levalbuterol aerosol inhaler for the treatment of asthma. Levalbuterol is the active isomer of albuterol and has been available in a nebulized solution for many years. This new formulation is marketed by Sepracor as Xopenex HFA. -
Clinical Briefs By Louis Kuritzky, MD
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout; Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients with Unstable Coronary Artery Disease; Dietary Fiber Intake and Risk of Colorectal Cancer